Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL LIPID PROFILE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL LIPID PROFILE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET GUIDE
2.2.4 COMPANY POSITIONING GRID
2.2.5 COMPANY MARKET SHARE ANALYSIS
2.2.6 MULTIVARIATE MODELLING
2.2.7 TOP TO BOTTOM ANALYSIS
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 VENDOR SHARE ANALYSIS
2.2.10 SALES VOLUME
2.2.11 EPIDEMIOLOGY MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL LIPID PROFILE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 EPIDEMIOLOGY
5.1 PREVALENCE OF HYPERTENSION, BY COUNTRY
5.2 PREVALENCE OF DIABETES, BY COUNTRY
5.3 PREVALENCE OF OBESITY, BY COUNTRY
5.4 PREVALENCE OF STRESS, BY COUNTRY
5.5 PREVALENCE OF HIGH TOTAL CHOLESTEROL, BY COUNTRY
5.6 PREVALENCE OF GENETIC DISORDERS, BY COUNTRY
5.7 PREVALENCE OF HEART DISORDERS, BY COUNTRY
6 PREMIUM INSIGHTS
6.1 PESTAL ANALYSIS
6.2 PORTER’S FIVE FORCES
6.3 KEY STRATEGIC INITIATIVES
7 GLOBAL LIPID PROFILE MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 DEVICES
7.2.1 LABORATORY BASED DEVICES
7.2.1.1. ANALYZERS
7.2.1.1.1. MARKET VALUE (USD MILLION)
7.2.1.1.2. MARKET VOLUME (UNITS)
7.2.1.1.3. AVERAGE SELLING PRICE (USD)
7.2.1.2. OTHERS
7.2.2 POINT OF CARE BASED DEVICES
7.2.2.1. CLIA-WAIVED POINT OF CARE TEST
7.2.2.1.1. MARKET VALUE (USD MILLION)
7.2.2.1.2. MARKET VOLUME (UNITS)
7.2.2.1.3. AVERAGE SELLING PRICE (USD)
7.2.2.2. SMARTPHONE-BASED POINT-OF-CARE TEST/IVD TEST
7.2.2.2.1. MARKET VALUE (USD MILLION)
7.2.2.2.2. MARKET VOLUME (UNITS)
7.2.2.2.3. AVERAGE SELLING PRICE (USD)
7.2.2.3. OTHERS
7.3 TEST KITS
7.3.1 TEST STRIPS
7.3.1.1. THREE-ANALYTE TEST STRIPS
7.3.1.1.1. MARKET VALUE (USD MILLION)
7.3.1.1.2. MARKET VOLUME (UNITS)
7.3.1.1.3. AVERAGE SELLING PRICE (USD)
7.3.1.2. DUAL-ANALYTE TEST STRIPS
7.3.1.2.1. MARKET VALUE (USD MILLION)
7.3.1.2.2. MARKET VOLUME (UNITS)
7.3.1.2.3. AVERAGE SELLING PRICE (USD)
7.3.1.3. SINGLE-ANALYTE TEST STRIPS
7.3.1.3.1. MARKET VALUE (USD MILLION)
7.3.1.3.2. MARKET VOLUME (UNITS)
7.3.1.3.3. AVERAGE SELLING PRICE (USD)
7.3.2 TEST CONTROLS
7.3.2.1. MULTI-CHEMISTRY CONTROLS
7.3.2.1.1. MARKET VALUE (USD MILLION)
7.3.2.1.2. MARKET VOLUME (UNITS)
7.3.2.1.3. AVERAGE SELLING PRICE (USD)
7.3.2.2. HDL CHOLESTROL CONTROLS
7.3.2.2.1. MARKET VALUE (USD MILLION)
7.3.2.2.2. MARKET VOLUME (UNITS)
7.3.2.2.3. AVERAGE SELLING PRICE (USD)
7.3.2.3. OTHERS
7.4 OTHERS
8 GLOBAL LIPID PROFILE MARKET, BY TYPE
8.1 OVERVIEW
8.2 TOTAL CHOLESTEROL
8.2.1 MARKET VALUE (USD)
8.2.2 NUMBER OF TESTS (UNITS)
8.2.3 PRICE PER TEST (USD)
8.3 LOW-DENSITY LIPOPROTEIN (LDL)
8.3.1 MARKET VALUE (USD)
8.3.2 NUMBER OF TESTS (UNITS)
8.3.3 PRICE PER TEST (USD)
8.4 HIGH-DENSITY LIPOPROTEIN (HDL)
8.4.1 MARKET VALUE (USD)
8.4.2 NUMBER OF TESTS (UNITS)
8.4.3 PRICE PER TEST (USD)
8.5 VERY LOW-DENSITY LIPOPROTEIN (VLDL) CHOLESTEROL
8.5.1 MARKET VALUE (USD)
8.5.2 NUMBER OF TESTS (UNITS)
8.5.3 PRICE PER TEST (USD)
8.6 TRIGLYCERIDES
8.6.1 MARKET VALUE (USD)
8.6.2 NUMBER OF TESTS (UNITS)
8.6.3 PRICE PER TEST (USD)
9 GLOBAL LIPID PROFILE MARKET, BY PATIENT POPULATION
9.1 OVERVIEW
9.2 PEDIATRIC
9.2.1 MALE
9.2.2 FEMALE
9.3 ADULT
9.3.1 MALE
9.3.2 FEMALE
9.4 GERIATRIC
9.4.1 MALE
9.4.2 FEMALE
10 GLOBAL LIPID PROFILE MARKET, BY SAMPLE TYPE
10.1 OVERVIEW
10.2 WHOLE BLOOD
10.3 FINGERTIP BLOOD
10.4 VENOUS BLOOD
11 GLOBAL LIPID PROFILE MARKET, BY INDICATION
11.1 OVERVIEW
11.2 HIGH BLOOD PRESSURE
11.2.1 DEVICES
11.2.2 TEST KITS
11.2.3 OTHERS
11.3 DIABETES / PRE-DIABETES
11.3.1 DEVICES
11.3.2 TEST KITS
11.3.3 OTHERS
11.4 OBESITY
11.4.1 DEVICES
11.4.2 TEST KITS
11.4.3 OTHERS
11.5 STRESS
11.5.1 DEVICES
11.5.2 TEST KITS
11.5.3 OTHERS
11.6 HIGH TOTAL CHOLESTEROL
11.6.1 DEVICES
11.6.2 TEST KITS
11.6.3 OTHERS
11.7 GENETIC DISEASE
11.7.1 DEVICES
11.7.2 TEST KITS
11.7.3 OTHERS
11.8 PRE-EXISTING HEART DISEASES
11.8.1 DEVICES
11.8.2 TEST KITS
11.8.3 OTHERS
11.9 OTHERS
12 GLOBAL LIPID PROFILE MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS & CLINICS
12.3 DIAGNOSTIC CENTERS
12.3.1 CLINICAL LABORATORIES
12.3.2 AMUBULATORY SURGICAL CENTERS
12.4 ACADEMIC & RESEARCH INSTITUTES
12.5 HOME CARE SETTINGD
12.6 OTHERS
13 GLOBAL LIPID PROFILE MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.4 ONLINE SALES
13.5 OTHERS
14 GLOBAL LIPID PROFILE MARKET, BY REGION
GLOBAL LIPID PROFILE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS
REPRESENTED IN THIS CHAPTER BY COUNTRY)
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.1.1. U.S. LIPID PROFILE MARKET, BY PRODUCT TYPE
14.1.1.2. U.S. LIPID PROFILE MARKET, BY TYPE
14.1.1.3. U.S. LIPID PROFILE MARKET, BY PATIENT POPULATION
14.1.1.4. U.S. LIPID PROFILE MARKET, BY SAMPLE TYPE
14.1.1.5. U.S. LIPID PROFILE MARKET, BY INDICATION
14.1.1.6. U.S. LIPID PROFILE MARKET, BY END USER
14.1.1.7. U.S. LIPID PROFILE MARKET, BY DISTRIBUTION CHANNEL
14.1.2 CANADA
14.1.3 MEXICO
14.2 EUROPE
14.2.1 GERMANY
14.2.2 FRANCE
14.2.3 U.K.
14.2.4 ITALY
14.2.5 SPAIN
14.2.6 RUSSIA
14.2.7 TURKEY
14.2.8 BELGIUM
14.2.9 DENMARK
14.2.10 NETHERLANDS
14.2.11 SWITZERLAND
14.2.12 SWEDEN
14.2.13 POLAND
14.2.14 NORWAY
14.2.15 FINLAND
14.2.16 REST OF EUROPE
14.3 ASIA-PACIFIC
14.3.1 JAPAN
14.3.2 CHINA
14.3.3 SOUTH KOREA
14.3.4 INDIA
14.3.5 AUSTRALIA
14.3.6 NEW ZEALAND
14.3.7 SINGAPORE
14.3.8 THAILAND
14.3.9 MALAYSIA
14.3.10 VIETNAM
14.3.11 TAIWAN
14.3.12 INDONESIA
14.3.13 PHILIPPINES
14.3.14 REST OF ASIA-PACIFIC
14.4 SOUTH AMERICA
14.4.1 BRAZIL
14.4.2 ARGENTINA
14.4.3 REST OF SOUTH AMERICA
14.5 MIDDLE EAST AND AFRICA
14.5.1 SOUTH AFRICA
14.5.2 SAUDI ARABIA
14.5.3 BAHRAIN
14.5.4 UAE
14.5.5 KUWAIT
14.5.6 OMAN
14.5.7 QATAR
14.5.8 EGYPT
14.5.9 ISRAEL
14.5.10 REST OF MIDDLE EAST AND AFRICA
14.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
15 GLOBAL LIPID PROFILE MARKET, SWOT AND DBMR ANALYSIS
16 GLOBAL LIPID PROFILE MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.3 COMPANY SHARE ANALYSIS: EUROPE
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16.5 MERGERS & ACQUISITIONS
16.6 NEW PRODUCT DEVELOPMENT & APPROVALS
16.7 EXPANSIONS
16.8 REGULATORY CHANGES
16.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
17 GLOBAL LIPID PROFILE MARKET, COMPANY PROFILE
17.1 ABBOTT
17.1.1 COMPANY OVERVIEW
17.1.2 REVENUE ANALYSIS
17.1.3 GEOGRAPHIC PRESENCE
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 CUROFIT
17.2.1 COMPANY OVERVIEW
17.2.2 REVENUE ANALYSIS
17.2.3 GEOGRAPHIC PRESENCE
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 HENRY SCHEIN, INC.
17.3.1 COMPANY OVERVIEW
17.3.2 REVENUE ANALYSIS
17.3.3 GEOGRAPHIC PRESENCE
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 PIXOTEST
17.4.1 COMPANY OVERVIEW
17.4.2 REVENUE ANALYSIS
17.4.3 GEOGRAPHIC PRESENCE
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
17.5.1 COMPANY OVERVIEW
17.5.2 REVENUE ANALYSIS
17.5.3 GEOGRAPHIC PRESENCE
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ACON LABORATORIES, INC.
17.6.1 COMPANY OVERVIEW
17.6.2 REVENUE ANALYSIS
17.6.3 GEOGRAPHIC PRESENCE
17.6.4 PRODUCT PORTFOLIO
17.6.5 RECENT DEVELOPMENTS
17.7 CRODA INTERNATIONAL PLC.
17.7.1 COMPANY OVERVIEW
17.7.2 REVENUE ANALYSIS
17.7.3 GEOGRAPHIC PRESENCE
17.7.4 PRODUCT PORTFOLIO
17.7.5 RECENT DEVELOPMENTS
17.8 BECKMAN COULTER, INC.
17.8.1 COMPANY OVERVIEW
17.8.2 REVENUE ANALYSIS
17.8.3 GEOGRAPHIC PRESENCE
17.8.4 PRODUCT PORTFOLIO
17.8.5 RECENT DEVELOPMENTS
17.9 F. HOFFMANN-LA ROCHE LTD
17.9.1 COMPANY OVERVIEW
17.9.2 REVENUE ANALYSIS
17.9.3 GEOGRAPHIC PRESENCE
17.9.4 PRODUCT PORTFOLIO
17.9.5 RECENT DEVELOPMENTS
17.1 BIO-RAD LABORATORIES, INC.
17.10.1 COMPANY OVERVIEW
17.10.2 REVENUE ANALYSIS
17.10.3 GEOGRAPHIC PRESENCE
17.10.4 PRODUCT PORTFOLIO
17.10.5 RECENT DEVELOPMENTS
17.11 EUROFINS SCIENTIFIC
17.11.1 COMPANY OVERVIEW
17.11.2 REVENUE ANALYSIS
17.11.3 GEOGRAPHIC PRESENCE
17.11.4 PRODUCT PORTFOLIO
17.11.5 RECENT DEVELOPMENTS
17.12 BOSTON HEART DIAGNOSTICS CORPORATION
17.12.1 COMPANY OVERVIEW
17.12.2 REVENUE ANALYSIS
17.12.3 GEOGRAPHIC PRESENCE
17.12.4 PRODUCT PORTFOLIO
17.12.5 RECENT DEVELOPMENTS
17.13 PTS DIAGNOSTICS
17.13.1 COMPANY OVERVIEW
17.13.2 REVENUE ANALYSIS
17.13.3 GEOGRAPHIC PRESENCE
17.13.4 PRODUCT PORTFOLIO
17.13.5 RECENT DEVELOPMENTS
17.14 QUEST DIAGNOSTICS
17.14.1 COMPANY OVERVIEW
17.14.2 REVENUE ANALYSIS
17.14.3 GEOGRAPHIC PRESENCE
17.14.4 PRODUCT PORTFOLIO
17.14.5 RECENT DEVELOPMENTS
17.15 RANDOX LABORATORIES LTD.
17.15.1 COMPANY OVERVIEW
17.15.2 REVENUE ANALYSIS
17.15.3 GEOGRAPHIC PRESENCE
17.15.4 PRODUCT PORTFOLIO
17.15.5 RECENT DEVELOPMENTS
17.16 SIEMENS HEALTHCARE PRIVATE LIMITED
17.16.1 COMPANY OVERVIEW
17.16.2 REVENUE ANALYSIS
17.16.3 GEOGRAPHIC PRESENCE
17.16.4 PRODUCT PORTFOLIO
17.16.5 RECENT DEVELOPMENTS
17.17 SONORA QUEST LABORATORIES
17.17.1 COMPANY OVERVIEW
17.17.2 REVENUE ANALYSIS
17.17.3 GEOGRAPHIC PRESENCE
17.17.4 PRODUCT PORTFOLIO
17.17.5 RECENT DEVELOPMENTS
17.18 BEAUMONT HEALTH
17.18.1 COMPANY OVERVIEW
17.18.2 REVENUE ANALYSIS
17.18.3 GEOGRAPHIC PRESENCE
17.18.4 PRODUCT PORTFOLIO
17.18.5 RECENT DEVELOPMENTS
17.19 WELLNESSFX
17.19.1 COMPANY OVERVIEW
17.19.2 REVENUE ANALYSIS
17.19.3 GEOGRAPHIC PRESENCE
17.19.4 PRODUCT PORTFOLIO
17.19.5 RECENT DEVELOPMENTS
17.2 THERMO FISHER SCIENTIFIC
17.20.1 COMPANY OVERVIEW
17.20.2 REVENUE ANALYSIS
17.20.3 GEOGRAPHIC PRESENCE
17.20.4 PRODUCT PORTFOLIO
17.20.5 RECENT DEVELOPMENTS
17.21 LUMIGENEX (SUZHOU) CO., LTD.
17.21.1 COMPANY OVERVIEW
17.21.2 REVENUE ANALYSIS
17.21.3 GEOGRAPHIC PRESENCE
17.21.4 PRODUCT PORTFOLIO
17.21.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
18 RELATED REPORTS
19 QUESTIONNAIRE
20 CONCLUSION
21 ABOUT DATA BRIDGE MARKET RESEARCH
